Autonomix Medical(AMIX)

Focus: Autonomix Medical is a publicly traded diagnostics company specializing in nervous system diagnostic solutions, based in The Woodlands, Texas. The company operates in a focused niche within the diagnostics segment with limited scale transparency.

Profile data last refreshed 22h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Autonomix Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Autonomix Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

FY2025

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

SEC Filings: 2 available

Financials (FY2025)

Help build intelligence for Autonomix Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Niche focus in nervous system diagnostics presents deep technical expertise opportunities in high-unmet-need area
Public company status provides equity upside and institutional stability versus pre-revenue biotech
Specialized market allows for differentiated positioning versus large diversified competitors

Watch Out For

Zero active job openings signal either full staffing, hiring freeze, or minimal growth trajectory
Significant cash burn ($15.4M net loss in FY2025 against only $9M cash) indicates runway concerns without demonstrated revenue
Empty product pipeline (no active trials, no listed products) raises questions about commercial viability and future growth catalysts

Generated by Claude from Autonomix Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo